3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Breast
1
Conditions
Neoplasms
1
Multiple Endocrine Neoplasia Type 1
1
Hereditary Sensory and Autonomic Neuropathies
1
Breast Neoplasms
1
Interventions
Trastuzumab
9
Capecitabine
7
trastuzumab deruxtecan
6
Paclitaxel
6
Fulvestrant
6
pertuzumab
5
eribulin
5
Gemcitabine
4
Cyclophosphamide
4
sacituzumab govitecan
3
Vinorelbine
3
Doxorubicin
3
Docetaxel
3
Ado-Trastuzumab Emtansine
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
ribociclib
2
palbociclib
2
olaparib
2
larotrectinib
2
exemestane
2
abemaciclib
2
Fluorouracil
2
Epirubicin
2
Carboplatin
2
ulixertinib
1
tucatinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
taxane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Breast Neoplasms
×
Alpelisib
×
Clear all
NCT02437318
2025-02-13
SOLAR-1
Novartis
Phase 3
Completed
572 enrolled
22 charts
1 FDA